Acalabrutinib (Calquence) as a single agent or in combination with obinutuzumab (Gazyva) significantly improved progression-free survival compared with obinutuzumab plus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia.
Oxaliplatin plus fluoropyrimidine and bevacizumab confers little therapeutic benefit to older patients with metastatic colorectal cancer.
Medical experts discuss the data that led to belumosudil’s FDA approval.
Patients with essential thrombocythemia who progressed to myelofibrosis had longer duration of disease, higher white blood cell counts, and lower hemoglobin levels at enrollment.
The FDA has approved subcutaneous atezolizumab for use in all indications as the intravenous formulation.
Dr Gadi leads a discussion surrounding HER2 mutation and overexpression across various cancer types.
The DUBLIN-3 trial showed plinabulin plus docetaxel improved survival in EGFR wild-type non–small cell lung cancer.
Ibrilatazar plus paclitaxel/carboplatin led to a 100% disease-control rate in patients with advanced/recurrent endometrial cancer and was well tolerated.
Alexandra Drakaki, MD, expands on the need to improve specific classifications in non–clear cell renal cell carcinoma.
Consuelo Bertossi, MD, discusses research elucidating the role and prognostic significance of TP53 mutations in chronic lymphocytic leukemia.
The FDA has granted orphan drug designation to tebapivat for the treatment of myelodysplastic syndromes.
